Apr 1
Proxy statement
PRE 14A
Meeting May 21, 2025
Proxy statement
FTH · Faeth Therapeutics, Inc. · Documents
Market Cap
$259.21M
Shares
25.84M
Volume · Nov 13
1.04M
Avg daily vol (3M)
482.56K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
2025
Mar 28
Current report
8-K
Financial results
Mar 28
Annual report
10-K
FY2024, ended Dec 31
Annual report for FY2024
Net loss $30.16M
Diluted EPS -$1.20
Mar 27
Current report
8-K
Regulation FD disclosure
Jan 7
Current report
8-K
Delisting notice or listing transfer
2024
Nov 14
Current report
8-K
Financial results
Nov 14
Quarterly report
10-Q
FY2024 Q3, ended Sep 30
Quarterly report for FY2024 Q3
Net loss $7.25M
Diluted EPS -$0.29
Oct 30
Current report
8-K
Events of Oct 25
Director or officer change, or executive pay
Sep 20
Current report
8-K
Events of Sep 17
Director or officer change, or executive pay
Aug 6
Current report
8-K
Financial results
Aug 6
Quarterly report
10-Q
FY2024 Q2, ended Jun 30
Quarterly report for FY2024 Q2
Net loss $7.14M
Diluted EPS -$0.28
Jul 12
Current report
8-K
Events of Jul 10
Delisting notice or listing transfer
Jun 27
Current report
8-K
Events of Jun 26
Director or officer change, or executive pay
Jun 13
Current report
8-K
Events of Jun 11
Shareholder vote results
Jun 3
Current report
8-K
Regulation FD disclosure
May 23
Current report
8-K
Regulation FD disclosure
May 9
Current report
8-K
Financial results
May 9
Quarterly report
10-Q
FY2024 Q1, ended Mar 31
Quarterly report for FY2024 Q1
Net loss $7.99M
Diluted EPS -$0.32
Apr 29
Proxy statement
DEF 14A
Meeting Jun 11, 2024
Proxy statement
Apr 29
Annual report to holders
ARS
Annual report to holders
Apr 29
Proxy statement
DEFA14A
Proxy statement
Apr 12
Current report
8-K
Events of Apr 11
Director or officer change, or executive pay
Apr 2
Current report
8-K
Events of Mar 27
Director or officer change, or executive pay
Mar 5
Current report
8-K
Entered into a material agreement, Change to shareholders' rights
Feb 29
Feb 28
Current report
8-K
Financial results
Feb 8
Current report
8-K
Events of Feb 5
Director or officer change, or executive pay, Other events
Jan 4
Current report
8-K
Regulation FD disclosure
2023
Nov 7
Current report
8-K
Financial results
Nov 7
Quarterly report
10-Q
FY2023 Q3, ended Sep 30
Quarterly report for FY2023 Q3
Net loss $7.12M
Diluted EPS -$0.28
Nov 6
Current report
8-K
Regulation FD disclosure
Nov 3
Current report
8-K
Regulation FD disclosure
Oct 20
Current report
8-K
Events of Oct 17
Delisting notice or listing transfer
Aug 3
Current report
8-K
Financial results
Aug 3
Quarterly report
10-Q
FY2023 Q2, ended Jun 30
Quarterly report for FY2023 Q2
Net loss $9.39M
Diluted EPS -$0.31
Jul 10
Current report
8-K
Shareholder vote results
Jun 27
Current report
8-K
Regulation FD disclosure
Jun 23
Current report
8-K
Entered into a material agreement, Change to shareholders' rights
Jun 15
Proxy statement
DEF 14A
Meeting Jul 10, 2023
Proxy statement
Jun 15
Annual report to holders
ARS
Annual report to holders
May 23
Current report
8-K
Entered into a material agreement
May 23
Proxy statement
DEFA14A
Proxy statement
May 9
Current report
8-K
Financial results
May 9
Quarterly report
10-Q
FY2023 Q1, ended Mar 31
Quarterly report for FY2023 Q1
Net loss $10.18M
Diluted EPS -$0.33
May 1
Annual report
10-K/A
Ended Dec 31
Annual report for the period ended Dec 31, 2022
Apr 20
Current report
8-K
Regulation FD disclosure
Mar 29
Annual report
10-K
FY2022, ended Dec 31
Annual report for FY2022
Net loss $48.59M
Diluted EPS -$1.58
Mar 28
Current report
8-K
Financial results
Mar 13
Current report
8-K
Regulation FD disclosure
Mar 10
Current report
8-K
Other events
Showing 51–100 of 144 documents
Key facts
CIK
1829802
CUSIP
81728A207
13F (30d)
41 filings
41 filers
Visit website
Investor relations